{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:56:20Z","timestamp":1793318180355,"version":"4.5.0"},"reference-count":199,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"unspecified","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008741","name":"European League Against Rheumatism","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2020,12,21]]},"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To summarise, by a systematic literature review (SLR), the evidence regarding pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis (D2T RA), informing the EULAR recommendations for the management of D2T RA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>PubMed, Embase and Cochrane databases were searched up to December 2019. Relevant papers were selected and appraised.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Two hundred seven (207) papers studied therapeutic strategies. Limited evidence was found on effective and safe disease-modifying antirheumatic drugs (DMARDs) in patients with comorbidities and other contraindications that limit DMARD options (patients with obesity, hepatitis B and C, risk of venous thromboembolisms, pregnancy and lactation). In patients who previously failed biological (b-)DMARDs, all currently used b\/targeted synthetic (ts-)DMARDs were found to be more effective than placebo. In patients who previously failed a tumour necrosis factor inhibitor (TNFi), there was a tendency of non-TNFi bDMARDs to be more effective than TNFis. Generally, effectiveness decreased in patients who previously failed a higher number of bDMARDs. Additionally, exercise, psychological, educational and self-management interventions were found to improve non-inflammatory complaints (mainly functional disability, pain, fatigue), education to improve goal setting, and self-management programmes, educational and psychological interventions to improve self-management.<\/jats:p>\n                  <jats:p>The identified evidence had several limitations: (1) no studies were found in patients with D2T RA specifically, (2) heterogeneous outcome criteria were used and (3) most studies had a moderate or high risk of bias.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This SLR underscores the scarcity of high-quality evidence on the pharmacological and non-pharmacological treatment of patients with D2T RA. Effectiveness of b\/tsDMARDs decreased in RA patients who had failed a higher number of bDMARDs and a subsequent b\/tsDMARD of a previously not targeted mechanism of action was somewhat more effective. Additionally, a beneficial effect of non-pharmacological interventions was found for improvement of non-inflammatory complaints, goal setting and self-management.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2020-001512","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T12:22:42Z","timestamp":1610108562000},"page":"e001512","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":83,"title":["Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4364-3183","authenticated-orcid":false,"given":"Nadia M T","family":"Roodenrijs","sequence":"first","affiliation":[{"name":"Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Hamar","sequence":"additional","affiliation":[{"name":"Rheumatology, University of Debrecen, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Kedves","sequence":"additional","affiliation":[{"name":"Rheumatology, Bacs-Kiskun Megyei Korhaz, Kecskemet, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Nagy","sequence":"additional","affiliation":[{"name":"Genetics, Cell- and Immunobiology & Rheumatology & Clinical Rheumatology, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M","family":"van Laar","sequence":"additional","affiliation":[{"name":"Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paco M J","family":"Welsing","sequence":"additional","affiliation":[{"name":"Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"2025090312532307000_7.1.e001512.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655"},{"key":"2025090312532307000_7.1.e001512.2","first-page":"1","article-title":"American College of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"2016","author":"Singh","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090312532307000_7.1.e001512.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212862"},{"key":"2025090312532307000_7.1.e001512.4","first-page":"1135","article-title":"Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need","volume":"57","author":"de Hair","year":"2017","journal-title":"Rheumatology"},{"key":"2025090312532307000_7.1.e001512.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213378"},{"key":"2025090312532307000_7.1.e001512.6","unstructured":"Nagy G , Roodenrijs NMT , Welsing PMJ . EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis 2020:annrheumdis-2020-217344."},{"key":"2025090312532307000_7.1.e001512.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213687"},{"key":"2025090312532307000_7.1.e001512.8","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-214147","article-title":"Correspondence to viewpoint \u2018Defining refractory rheumatoid arthritis\u2019 by Buch","volume":"78","author":"Roodenrijs","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025090312532307000_7.1.e001512.9","article-title":"Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease","author":"Roodenrijs","year":"2020","journal-title":"Rheumatology"},{"key":"2025090312532307000_7.1.e001512.10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140976"},{"key":"2025090312532307000_7.1.e001512.11","doi-asserted-by":"crossref","unstructured":"Roodenrijs NMT , Kedves M , Hamar A . Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review Informing the 2020 EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. Manuscript under review.","DOI":"10.1136\/rmdopen-2020-001511"},{"key":"2025090312532307000_7.1.e001512.12","first-page":"8","article-title":"Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations","volume":"2015","author":"van der Heijde","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2025090312532307000_7.1.e001512.13","unstructured":"Thompson M , Tiwari A , Fu R . A framework to facilitate the use of systematic reviews and meta-analyses in the design of primary research studies. Rockville, MD agency Healthc. Res. Qual 2012 http:\/\/www.ncbi.nlm.nih.gov\/books\/ NBK83621\/ (accessed 13 Nov 2019)."},{"key":"2025090312532307000_7.1.e001512.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2025090312532307000_7.1.e001512.15","doi-asserted-by":"publisher","DOI":"10.1059\/0003-4819-155-8-201110180-00009"},{"key":"2025090312532307000_7.1.e001512.16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008"},{"key":"2025090312532307000_7.1.e001512.17","doi-asserted-by":"crossref","first-page":":249.1","DOI":"10.1136\/annrheumdis-2017-eular.3759","article-title":"THU0127 the dynamics of mental disorders frequency in complex dmards, biologics and antidepressants treatment of rheumatoid arthritis patients","volume":"76","author":"Abramkin","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025090312532307000_7.1.e001512.18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker190"},{"key":"2025090312532307000_7.1.e001512.19","first-page":"849.1","article-title":"SAT0202 efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy in patients with active rheumatoid arthritis in the phase 3 monarch study, including subpopulations","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025090312532307000_7.1.e001512.20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/926836","article-title":"HBV reactivation in patients treated with antitumor necrosis factor-alpha (TNF-\u03b1) agents for rheumatic and dermatologic conditions: a systematic review and meta-analysis","volume":"2014","author":"Cantini","year":"2014","journal-title":"Int J Rheumatol"},{"key":"2025090312532307000_7.1.e001512.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206711"},{"key":"2025090312532307000_7.1.e001512.22","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/1756-185X.13010","article-title":"Short-Course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation","volume":"20","author":"Chen","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2025090312532307000_7.1.e001512.23","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40264-016-0431-z","article-title":"Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis","volume":"39","author":"Clowse","year":"2016","journal-title":"Drug Saf"},{"key":"2025090312532307000_7.1.e001512.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214261"},{"key":"2025090312532307000_7.1.e001512.25","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1007\/s10067-016-3422-7","article-title":"The effect of etanercept on traditional metabolic risk factors for cardiovascular disease in patients with rheumatoid arthritis","volume":"35","author":"Deodhar","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2025090312532307000_7.1.e001512.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-eular.3110"},{"key":"2025090312532307000_7.1.e001512.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208840"},{"key":"2025090312532307000_7.1.e001512.28","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21768"},{"key":"2025090312532307000_7.1.e001512.29","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-018-0797-2","article-title":"Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial","volume":"17","author":"Hang","year":"2018","journal-title":"Lipids Health Dis"},{"key":"2025090312532307000_7.1.e001512.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.05.004"},{"key":"2025090312532307000_7.1.e001512.31","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130658"},{"key":"2025090312532307000_7.1.e001512.32","first-page":"619","article-title":"Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis","volume":"7","author":"Ikonomidis","year":"2014","journal-title":"Circulation"},{"key":"2025090312532307000_7.1.e001512.33","doi-asserted-by":"publisher","DOI":"10.1002\/art.30136"},{"key":"2025090312532307000_7.1.e001512.34","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10067-015-2962-6","article-title":"Tumor necrosis factor-\u03b1 antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study","volume":"34","author":"Lin","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2025090312532307000_7.1.e001512.35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206695"},{"key":"2025090312532307000_7.1.e001512.36","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.semarthrit.2018.07.011","article-title":"Safety of anti-rheumatic drugs in men trying to conceive: a systematic review and analysis of published evidence","volume":"48","author":"Mouyis","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312532307000_7.1.e001512.37","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes190"},{"key":"2025090312532307000_7.1.e001512.38","doi-asserted-by":"crossref","DOI":"10.3390\/nu9050428","article-title":"Vitamin D and calcium are required during denosumab treatment in osteoporosis with rheumatoid arthritis","volume":"9","author":"Nakamura","year":"2017","journal-title":"Nutrients"},{"key":"2025090312532307000_7.1.e001512.39","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/acr.22786","article-title":"Safety of abatacept in rheumatoid arthritis with serologic evidence of past or present hepatitis B virus infection","volume":"68","author":"Padovan","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2025090312532307000_7.1.e001512.40","first-page":"102","article-title":"Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study","volume":"36","author":"Papalopoulos","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312532307000_7.1.e001512.41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002901","article-title":"Anti-Interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (track): a multicentre, open-label, randomised controlled trial","volume":"16","author":"Ruscitti","year":"2019","journal-title":"PLoS Med"},{"key":"2025090312532307000_7.1.e001512.42","doi-asserted-by":"crossref","unstructured":"Sammaritano LR , Bermas BL , Chakravarty EE . American College of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 2020;2020.","DOI":"10.1002\/art.41191"},{"key":"2025090312532307000_7.1.e001512.43","doi-asserted-by":"crossref","unstructured":"Sepriano A , Kerschbaumer A , Smolen JS , et al . Safety of synthetic and biological DMARDs: a systematic literature review Informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2020:annrheumdis-2019-216653. doi:10.1136\/annrheumdis-2019-216653","DOI":"10.1136\/annrheumdis-2019-216653"},{"key":"2025090312532307000_7.1.e001512.44","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.clinthera.2017.01.008","article-title":"Monthly oral ibandronate reduces bone loss in Korean women with rheumatoid arthritis and osteopenia receiving long-term glucocorticoids: a 48-week double-blinded randomized placebo-controlled investigator-initiated trial","volume":"39","author":"Shin","year":"2017","journal-title":"Clin Ther"},{"key":"2025090312532307000_7.1.e001512.45","first-page":"964.1","article-title":"SAT0207 depressive symptoms in patients with rheumatoid arthritis in sarilumab target and mobility trials and impact of treatment","volume":"77","author":"Strand","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025090312532307000_7.1.e001512.46","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.semarthrit.2019.03.007","article-title":"Comparative safety of abatacept in rheumatoid arthritis with COPD: a real-world population-based observational study","volume":"49","author":"Suissa","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312532307000_7.1.e001512.47","doi-asserted-by":"publisher","DOI":"10.1002\/art.22070"},{"key":"2025090312532307000_7.1.e001512.48","unstructured":"Yoo D-H , Park W , Suh C-H . Rituximab is effective in the treatment of rheumatoid arthritis irrespective of body mass index; up to 48 weeks results from phase 3 study. Arthritis Rheumatol 2017;69."},{"key":"2025090312532307000_7.1.e001512.49","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1007\/s10067-016-3227-8","article-title":"Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis","volume":"35","author":"Akiyama","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2025090312532307000_7.1.e001512.50","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0140-6736(17)30401-4","article-title":"Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study","volume":"389","author":"Aletaha","year":"2017","journal-title":"The Lancet"},{"key":"2025090312532307000_7.1.e001512.51","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1007\/s10067-018-4164-5","article-title":"Niclosamide as an adjuvant to etanercept in treatment patients with active rheumatoid arthritis: an 8-week randomized controlled pilot study","volume":"37","author":"Al-Gareeb","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2025090312532307000_7.1.e001512.52","doi-asserted-by":"publisher","DOI":"10.1186\/ar2848"},{"key":"2025090312532307000_7.1.e001512.53","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101324"},{"key":"2025090312532307000_7.1.e001512.54","doi-asserted-by":"publisher","DOI":"10.3310\/hta22440"},{"key":"2025090312532307000_7.1.e001512.55","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"The Lancet"},{"key":"2025090312532307000_7.1.e001512.56","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-207178"},{"key":"2025090312532307000_7.1.e001512.57","doi-asserted-by":"crossref","first-page":"271.3","DOI":"10.1136\/annrheumdis-2017-eular.2346","article-title":"THU0185 comparison of tofacitinib safety and efficacy in rheumatoid arthritis patients with inadequate response to conventional synthetic dmards, or to one or more biological dmards","volume":"76","author":"Charles-Schoeman","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025090312532307000_7.1.e001512.58","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204714"},{"key":"2025090312532307000_7.1.e001512.59","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2012.729607"},{"key":"2025090312532307000_7.1.e001512.60","first-page":"795","article-title":"The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis","volume":"23","author":"Cohen","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312532307000_7.1.e001512.61","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-eular.4469"},{"key":"2025090312532307000_7.1.e001512.62","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204417"},{"key":"2025090312532307000_7.1.e001512.63","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s10067-019-04508-2","article-title":"Efficacy and safety profile of intravenous tocilizumab versus intravenous abatacept in treating female Saudi Arabian patients with active moderate-to-severe rheumatoid arthritis","volume":"38","author":"Elmedany","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2025090312532307000_7.1.e001512.64","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092932"},{"key":"2025090312532307000_7.1.e001512.65","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203993"},{"key":"2025090312532307000_7.1.e001512.66","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.105064"},{"key":"2025090312532307000_7.1.e001512.67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109071"},{"key":"2025090312532307000_7.1.e001512.68","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/art.39944","article-title":"Sarilumab and Nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312532307000_7.1.e001512.69","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-eular.2281"},{"key":"2025090312532307000_7.1.e001512.70","doi-asserted-by":"publisher","DOI":"10.1002\/art.30114"},{"key":"2025090312532307000_7.1.e001512.71","doi-asserted-by":"publisher","DOI":"10.1002\/art.30373"},{"key":"2025090312532307000_7.1.e001512.72","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202775"},{"key":"2025090312532307000_7.1.e001512.73","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/art.38617","article-title":"A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors","volume":"66","author":"Genovese","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025090312532307000_7.1.e001512.74","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140238"},{"key":"2025090312532307000_7.1.e001512.75","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204760"},{"key":"2025090312532307000_7.1.e001512.76","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025090312532307000_7.1.e001512.77","first-page":"Suppl 10","article-title":"Improvements in Remission and Low Disease Activity Are Achieved with Ongoing Sarilumab Treatment, in Patients with Rheumatoid Arthritis in 2 Phase 3 Studies - ACR Meeting Abstracts","volume":"69","author":"Genovese","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312532307000_7.1.e001512.78","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/rheumatology\/kex489","article-title":"Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis","volume":"57","author":"Genovese","year":"2018","journal-title":"Rheumatology"},{"key":"2025090312532307000_7.1.e001512.79","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31116-4"},{"key":"2025090312532307000_7.1.e001512.80","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9055"},{"key":"2025090312532307000_7.1.e001512.81","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201324"},{"key":"2025090312532307000_7.1.e001512.82","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1017\/S0266462314000221","article-title":"Rituximab and tocilizumab for the treatment of rheumatoid arthritis","volume":"30","author":"Gonz\u00e1lez-Vacarezza","year":"2014","journal-title":"Int J Technol Assess Health Care"},{"key":"2025090312532307000_7.1.e001512.83","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.13512"},{"key":"2025090312532307000_7.1.e001512.84","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l67"},{"key":"2025090312532307000_7.1.e001512.85","doi-asserted-by":"publisher","DOI":"10.1002\/art.30194"},{"key":"2025090312532307000_7.1.e001512.86","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13075-015-0776-1","article-title":"Comparative effectiveness and safety of rituximab versus subsequent anti\u2013tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti\u2013tumor necrosis factor therapies in the United States Corrona registry","volume":"17","author":"Harrold","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2025090312532307000_7.1.e001512.87","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141043"},{"key":"2025090312532307000_7.1.e001512.88","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203936"},{"key":"2025090312532307000_7.1.e001512.89","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1179-7"},{"key":"2025090312532307000_7.1.e001512.90","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s40744-018-0127-1","article-title":"Real-World comparative effectiveness of tocilizumab monotherapy vs. tumor necrosis factor inhibitors with methotrexate in patients with rheumatoid arthritis","volume":"5","author":"Harrold","year":"2018","journal-title":"Rheumatol Ther"},{"key":"2025090312532307000_7.1.e001512.91","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2711-2"},{"key":"2025090312532307000_7.1.e001512.92","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1007\/s10067-019-04595-1","article-title":"Efficacy and safety of secukinumab in active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis of phase III randomized controlled trials","volume":"38","author":"Huang","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2025090312532307000_7.1.e001512.93","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2147\/BTT.S32244","article-title":"Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNF\u03b1 blocker failure","volume":"6","author":"Kekow","year":"2012","journal-title":"Biol Targets Ther"},{"key":"2025090312532307000_7.1.e001512.94","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s12272-014-0337-1","article-title":"Comparative effectiveness of cycling of tumor necrosis factor-\u03b1 (TNF-\u03b1) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-\u03b1 inhibitor using a Bayesian approach","volume":"37","author":"Kim","year":"2014","journal-title":"Arch Pharm Res"},{"key":"2025090312532307000_7.1.e001512.95","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/art.39801","article-title":"A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy","volume":"68","author":"Kremer","year":"2016","journal-title":"Arthritis & Rheumatology"},{"key":"2025090312532307000_7.1.e001512.96","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212845"},{"key":"2025090312532307000_7.1.e001512.97","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/1756-185X.12822","article-title":"Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled tri","volume":"19","author":"Lee","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"2025090312532307000_7.1.e001512.98","doi-asserted-by":"publisher","DOI":"10.3310\/hta15140"},{"key":"2025090312532307000_7.1.e001512.99","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210713"},{"key":"2025090312532307000_7.1.e001512.100","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/14397595.2017.1332507","article-title":"A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: results of the 12-week double-blind period","volume":"28","author":"Ogata","year":"2018","journal-title":"Modern Rheumatology"},{"key":"2025090312532307000_7.1.e001512.101","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12845"},{"key":"2025090312532307000_7.1.e001512.102","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.099218"},{"key":"2025090312532307000_7.1.e001512.103","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000037","article-title":"Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study","volume":"1","author":"Schiff","year":"2015","journal-title":"RMD Open"},{"key":"2025090312532307000_7.1.e001512.104","doi-asserted-by":"crossref","unstructured":"Singh JA , Hossain A , Tanjong Ghogomu E , et al . Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. Cochrane Database Syst Rev 2017;74.doi:10.1002\/14651858.CD012591","DOI":"10.1002\/14651858.CD012591"},{"key":"2025090312532307000_7.1.e001512.105","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203435"},{"key":"2025090312532307000_7.1.e001512.106","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","article-title":"Head-To-Head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study","volume":"388","author":"Smolen","year":"2016","journal-title":"The Lancet"},{"key":"2025090312532307000_7.1.e001512.107","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/acr.21663","article-title":"Rituximab or a second anti\u2013tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti\u2013tumor necrosis factor therapy? comparative analysis from the British Society for rheumatology biologics register","volume":"64","author":"Soliman","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2025090312532307000_7.1.e001512.108","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22453"},{"key":"2025090312532307000_7.1.e001512.109","doi-asserted-by":"publisher","DOI":"10.1002\/art.33353"},{"key":"2025090312532307000_7.1.e001512.110","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s00296-015-3283-4","article-title":"Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use","volume":"35","author":"Takahashi","year":"2015","journal-title":"Rheumatol Int"},{"key":"2025090312532307000_7.1.e001512.111","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/14397595.2015.1074648","article-title":"Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: results from a randomized phase II trial","volume":"26","author":"Takeuchi","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2025090312532307000_7.1.e001512.112","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.reuma.2015.11.019","article-title":"VARIAR study: assessment of short-term efficacy and safety of rituximab compared to an tumor necrosis factor alpha antagonists as second-line drug therapy in patients with rheumatoid arthritis refractory to a first tumor necrosis factor alpha antagonist","volume":"12","author":"Torrente-Segarra","year":"2016","journal-title":"Reumatol Cl\u00ednica"},{"key":"2025090312532307000_7.1.e001512.113","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1002\/art.39262","article-title":"Safety and efficacy of Atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, Double\u2010Blind, Placebo\u2010Controlled pilot trial","volume":"67","author":"van Vollenhoven","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090312532307000_7.1.e001512.114","doi-asserted-by":"crossref","first-page":"573.2","DOI":"10.1136\/annrheumdis-2017-eular.5472","article-title":"FRI0234 choice of biologic therapy following rituximab: influencing factors in a French multicenter cohort of rheumatoid arthritis","volume":"76","author":"Vial","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025090312532307000_7.1.e001512.115","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.clinthera.2016.11.004","article-title":"Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors: results from a network meta-analysis","volume":"38","author":"Vieira","year":"2016","journal-title":"Clin Ther"},{"key":"2025090312532307000_7.1.e001512.116","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204544"},{"key":"2025090312532307000_7.1.e001512.117","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev297"},{"key":"2025090312532307000_7.1.e001512.118","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s12325-017-0578-8","article-title":"Treatment persistence and clinical outcomes of tumor necrosis factor inhibitor cycling or switching to a new mechanism of action therapy: real-world observational study of rheumatoid arthritis patients in the United States with prior tumor necrosis factor inhibitor therapy","volume":"34","author":"Wei","year":"2017","journal-title":"Adv Ther"},{"key":"2025090312532307000_7.1.e001512.119","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/art.40323","article-title":"A Randomized Phase II b Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis","volume":"70","author":"Weinblatt","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025090312532307000_7.1.e001512.120","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-eular.3083"},{"key":"2025090312532307000_7.1.e001512.121","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10067-017-3806-3","article-title":"Comparison of the effectiveness on intra-articular and subcutaneous TNF inhibitor in rheumatoid arthritis patients","volume":"37","author":"Zhang","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2025090312532307000_7.1.e001512.122","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2010.01.010"},{"key":"2025090312532307000_7.1.e001512.123","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.4066\/biomedicalresearch.29-17-2906","article-title":"The effect of Siwan therapy in management of patients with rheumatoid arthritis: a single blind randomized controlled trial","volume":"29","author":"Allam","year":"2018","journal-title":"Biomed Res"},{"key":"2025090312532307000_7.1.e001512.124","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-013-2819-8"},{"key":"2025090312532307000_7.1.e001512.125","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1080\/07399332.2018.1438438","article-title":"Effectiveness of self-management program on arthritis symptoms among older women: a randomized controlled trial study","volume":"39","author":"Anvar","year":"2018","journal-title":"Health Care Women Int"},{"key":"2025090312532307000_7.1.e001512.126","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/msc.1112","article-title":"Walking is a feasible physical activity for people with rheumatoid arthritis: a feasibility randomized controlled trial","volume":"14","author":"Baxter","year":"2016","journal-title":"Musculoskeletal Care"},{"key":"2025090312532307000_7.1.e001512.127","doi-asserted-by":"crossref","unstructured":"Cameron M , Gagnier JJ , Chrubasik S . Herbal therapy for treating rheumatoid arthritis. Cochrane Database Syst Rev 2011:CD002948.","DOI":"10.1002\/14651858.CD002948.pub2"},{"key":"2025090312532307000_7.1.e001512.128","doi-asserted-by":"crossref","first-page":"7006290020p1","DOI":"10.5014\/ajot.2016.021386","article-title":"Systematic review of educational interventions for rheumatoid arthritis","volume":"70","author":"Carandang","year":"2016","journal-title":"Am J Occup Ther"},{"key":"2025090312532307000_7.1.e001512.129","doi-asserted-by":"publisher","DOI":"10.2522\/ptj.20070039"},{"key":"2025090312532307000_7.1.e001512.130","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000481","article-title":"Efficacy of embedded nurse-led versus conventional physician-led follow-up in rheumatoid arthritis: a systematic review and meta-analysis","volume":"3","author":"de Thurah","year":"2017","journal-title":"RMD Open"},{"key":"2025090312532307000_7.1.e001512.131","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/acr.23280","article-title":"Tele-Health followup strategy for tight control of disease activity in rheumatoid arthritis: results of a randomized controlled trial","volume":"70","author":"de Thurah","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2025090312532307000_7.1.e001512.132","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-018-0787-4","article-title":"Systematic review and meta-analysis: Mindfulness-Based interventions for rheumatoid arthritis","volume":"20","author":"DiRenzo","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"2025090312532307000_7.1.e001512.133","doi-asserted-by":"publisher","DOI":"10.1111\/j.1756-185X.2010.01563.x"},{"key":"2025090312532307000_7.1.e001512.134","doi-asserted-by":"publisher","DOI":"10.1037\/0278-6133.26.3.241"},{"key":"2025090312532307000_7.1.e001512.135","first-page":"899","article-title":"Arthritis education: the integration of patient-reported outcome measures and patient self-management","volume":"30","author":"El Miedany","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312532307000_7.1.e001512.136","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2474-8-23","article-title":"A pragmatic randomised controlled trial of hydrotherapy and land exercises on overall well being and quality of life in rheumatoid arthritis","volume":"8","author":"Eversden","year":"2007","journal-title":"BMC Musculoskelet Disord"},{"key":"2025090312532307000_7.1.e001512.137","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2015.09.022"},{"key":"2025090312532307000_7.1.e001512.138","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/j.pain.0000000000000845","article-title":"A tailored-guided Internet-based cognitive-behavioral intervention for patients with rheumatoid arthritis as an adjunct to standard rheumatological care","volume":"158","author":"Ferwerda","year":"2017","journal-title":"Pain"},{"key":"2025090312532307000_7.1.e001512.139","doi-asserted-by":"crossref","unstructured":"Fidahic M , Jelicic Kadic A , Radic M , et al . Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev 2017;15.doi:10.1002\/14651858.CD012095.pub2","DOI":"10.1002\/14651858.CD012095.pub2"},{"key":"2025090312532307000_7.1.e001512.140","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5152\/tjr.2011.020","article-title":"Long-Term effects of comprehensive inpatient rehabilitation on function and disease activity in patients with chronic rheumatoid arthritis and ankylosing spondylitis","volume":"26","author":"Figen","year":"2011","journal-title":"Turkish J Rheumatol"},{"key":"2025090312532307000_7.1.e001512.141","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/acr.22727","article-title":"Efficacy, tolerability, and safety of cannabinoid treatments in the rheumatic diseases: a systematic review of randomized controlled trials","volume":"68","author":"Fitzcharles","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2025090312532307000_7.1.e001512.142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/409174","article-title":"Effects of whole-body cryotherapy in comparison with other physical modalities used with Kinesitherapy in rheumatoid arthritis","volume":"2015","author":"Gizi\u0144ska","year":"2015","journal-title":"Biomed Res Int"},{"key":"2025090312532307000_7.1.e001512.143","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.pmn.2016.01.004","article-title":"The effects of Aromatherapy massage and reflexology on pain and fatigue in patients with rheumatoid arthritis: a randomized controlled trial","volume":"17","author":"Gok Metin","year":"2016","journal-title":"Pain Management Nursing"},{"key":"2025090312532307000_7.1.e001512.144","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2002.001511"},{"key":"2025090312532307000_7.1.e001512.145","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38265.493773.8F"},{"key":"2025090312532307000_7.1.e001512.146","doi-asserted-by":"publisher","DOI":"10.3310\/hta23010"},{"key":"2025090312532307000_7.1.e001512.147","first-page":"CD006853","article-title":"Dynamic exercise programs (aerobic capacity and\/or muscle strength training) in patients with rheumatoid arthritis","volume":"2009","author":"Hurkmans","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2025090312532307000_7.1.e001512.148","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.129270"},{"key":"2025090312532307000_7.1.e001512.149","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s00296-013-2692-5","article-title":"Effects of different local cryotherapies on systemic levels of TNF-\u03b1, IL-6, and clinical parameters in active rheumatoid arthritis","volume":"33","author":"Jastrz\u0105bek","year":"2013","journal-title":"Rheumatol Int"},{"key":"2025090312532307000_7.1.e001512.150","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.wjam.2018.06.010","article-title":"Influence of acupotomy loosing on IL-6, IL-10 and TNF-\u03b1 in synovial fluid of rheumatoid arthritis patients with elbow joint stiffness","volume":"28","author":"Jiang","year":"2018","journal-title":"World J Acupunct - Moxibustion"},{"key":"2025090312532307000_7.1.e001512.151","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009355813"},{"key":"2025090312532307000_7.1.e001512.152","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10067-013-2425-x","article-title":"Targeting motivation and self-regulation to increase physical activity among patients with rheumatoid arthritis: a randomised controlled trial","volume":"34","author":"Knittle","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2025090312532307000_7.1.e001512.153","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s00393-018-0521-7","article-title":"A\u00a0brief report on the clinical trial on neural mobilization exercise for joint pain in patients with rheumatoid arthritis","volume":"78","author":"Lau","year":"2019","journal-title":"Z Rheumatol"},{"key":"2025090312532307000_7.1.e001512.154","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem151"},{"key":"2025090312532307000_7.1.e001512.155","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006140","article-title":"Bee venom acupuncture for rheumatoid arthritis: a systematic review of randomised clinical trials","volume":"4","author":"Lee","year":"2014","journal-title":"BMJ Open"},{"key":"2025090312532307000_7.1.e001512.156","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150550"},{"key":"2025090312532307000_7.1.e001512.157","doi-asserted-by":"publisher","DOI":"10.1002\/art.24563"},{"key":"2025090312532307000_7.1.e001512.158","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes133"},{"key":"2025090312532307000_7.1.e001512.159","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22102"},{"key":"2025090312532307000_7.1.e001512.160","doi-asserted-by":"crossref","DOI":"10.2196\/12221","article-title":"A mobile APP with optical imaging for the self-management of hand rheumatoid arthritis: pilot study","volume":"6","author":"Mollard","year":"2018","journal-title":"JMIR Mhealth Uhealth"},{"key":"2025090312532307000_7.1.e001512.161","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00296-016-3518-z","article-title":"Evaluation of the impact of nursing clinics in the rheumatology services","volume":"36","author":"Mu\u00f1oz-Fern\u00e1ndez","year":"2016","journal-title":"Rheumatol Int"},{"key":"2025090312532307000_7.1.e001512.162","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijnurstu.2018.03.008","article-title":"The evidence base for psychological interventions for rheumatoid arthritis: a systematic review of reviews","volume":"82","author":"Prothero","year":"2018","journal-title":"Int J Nurs Stud"},{"key":"2025090312532307000_7.1.e001512.163","doi-asserted-by":"crossref","unstructured":"Richards BL , Whittle SL , Buchbinder R . Antidepressants for pain management in rheumatoid arthritis. Cochrane Database Syst Rev 2011.","DOI":"10.1002\/14651858.CD008920"},{"key":"2025090312532307000_7.1.e001512.164","first-page":"474","article-title":"Balneotherapy and rheumatoid arthritis: a randomized control trial","volume":"18","author":"Santos","year":"2016","journal-title":"Isr Med Assoc J"},{"key":"2025090312532307000_7.1.e001512.165","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.11124\/JBISRIR-D-18-00020","article-title":"Effectiveness of non-pharmacological and non-surgical interventions for rheumatoid arthritis","volume":"17","author":"Santos","year":"2019","journal-title":"JBI database Syst Rev Implement reports"},{"key":"2025090312532307000_7.1.e001512.166","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/PHM.0000000000000564","article-title":"Effectiveness of aquatic exercises in women with rheumatoid arthritis: a randomized, controlled, 16-Week Intervention-The Hydra trial","volume":"96","author":"Siqueira","year":"2017","journal-title":"Am J Phys Med Rehabil"},{"key":"2025090312532307000_7.1.e001512.167","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1357633X18768400","article-title":"Web-Based rehabilitation interventions for people with rheumatoid arthritis: a systematic review","volume":"25","author":"Srikesavan","year":"2019","journal-title":"J Telemed Telecare"},{"key":"2025090312532307000_7.1.e001512.168","doi-asserted-by":"publisher","DOI":"10.1002\/art.10665"},{"key":"2025090312532307000_7.1.e001512.169","first-page":"4972","article-title":"Patient satisfaction after nurse-led care in Chinese patients with rheumatoid arthritis: a China study","volume":"28","author":"Wang","year":"2017","journal-title":"Biomed Res"},{"key":"2025090312532307000_7.1.e001512.170","doi-asserted-by":"crossref","unstructured":"Whittle SL , Richards BL , Husni E , et al . Opioid therapy for treating rheumatoid arthritis pain. Cochrane Database Syst Rev 2011;23.doi:10.1002\/14651858.CD003113.pub3","DOI":"10.1002\/14651858.CD003113.pub3"},{"key":"2025090312532307000_7.1.e001512.171","doi-asserted-by":"crossref","unstructured":"Williams MA , Srikesavan C , Heine PJ , et al . Exercise for rheumatoid arthritis of the hand. Cochrane Database Syst Rev 2018;32.doi:10.1002\/14651858.CD003832.pub3","DOI":"10.1002\/14651858.CD003832.pub3"},{"key":"2025090312532307000_7.1.e001512.172","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/acr.23541","article-title":"Experience and context shape patient and clinician goals for treatment of rheumatoid arthritis: a qualitative study","volume":"70","author":"Barton","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2025090312532307000_7.1.e001512.173","doi-asserted-by":"crossref","DOI":"10.1186\/s12955-018-1035-3","article-title":"Comparison of patient and physician perspectives in the management of rheumatoid arthritis: results from global physician- and patient-based surveys","volume":"16","author":"Gibofsky","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"2025090312532307000_7.1.e001512.174","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-eular.4405","article-title":"AB0222 differences of disease impression and treatment expectation in rheumatoid arthritis patients with different disease activity","volume":"77","author":"Torikai","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025090312532307000_7.1.e001512.175","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/acr.21657","article-title":"Decision tool to improve the quality of care in rheumatoid arthritis","volume":"64","author":"Fraenkel","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2025090312532307000_7.1.e001512.176","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/acr.22659","article-title":"Use of decision support for improved knowledge, values clarification, and informed choice in patients with rheumatoid arthritis","volume":"67","author":"Fraenkel","year":"2015","journal-title":"Arthritis Care Res"},{"key":"2025090312532307000_7.1.e001512.177","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/acr.22319","article-title":"Proof-Of-Concept study of a web-based methotrexate decision aid for patients with rheumatoid arthritis","volume":"66","author":"LC","year":"2014","journal-title":"Arthritis Care Res"},{"key":"2025090312532307000_7.1.e001512.178","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/acr.23287","article-title":"Effects of a web-based patient decision aid on biologic and small-molecule agents for rheumatoid arthritis: results from a proof-of-concept study","volume":"70","author":"LC","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2025090312532307000_7.1.e001512.179","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket374"},{"key":"2025090312532307000_7.1.e001512.180","doi-asserted-by":"crossref","first-page":"965","DOI":"10.12968\/bjon.2010.19.15.77692","article-title":"Self-helplessness in arthritis: an important but overlooked index","volume":"19","author":"Palmer","year":"2010","journal-title":"Br J Nurs"},{"key":"2025090312532307000_7.1.e001512.181","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/art.1780280310","article-title":"Assessing physician\/patient perceptions in rheumatoid arthritis. A vital component in patient education","volume":"28","author":"Silvers","year":"1985","journal-title":"Arthritis Rheum"},{"key":"2025090312532307000_7.1.e001512.182","doi-asserted-by":"publisher","DOI":"10.1177\/1073191103258144"},{"key":"2025090312532307000_7.1.e001512.183","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.4.373"},{"key":"2025090312532307000_7.1.e001512.184","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.04.001"},{"key":"2025090312532307000_7.1.e001512.185","first-page":"231","article-title":"A randomized controlled trial to evaluate the efficacy of community based physical therapy in the treatment of people with rheumatoid arthritis","volume":"25","author":"Bell","year":"1998","journal-title":"J Rheumatol"},{"key":"2025090312532307000_7.1.e001512.186","doi-asserted-by":"publisher","DOI":"10.2522\/ptj.20090010"},{"key":"2025090312532307000_7.1.e001512.187","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.144691"},{"key":"2025090312532307000_7.1.e001512.188","first-page":"12","article-title":"The effect of educational program on self-efficacy of women with rheumatoid arthritis: a randomized controlled clinical trial","volume":"6","author":"Hosseini Moghadam","year":"2018","journal-title":"Int J community based Nurs midwifery"},{"key":"2025090312532307000_7.1.e001512.189","first-page":"165","article-title":"Improvements following short term home based physical therapy are maintained at one year in people with moderate to severe rheumatoid arthritis","volume":"28","author":"Lineker","year":"2001","journal-title":"J Rheumatol"},{"key":"2025090312532307000_7.1.e001512.190","doi-asserted-by":"publisher","DOI":"10.1002\/art.23817"},{"key":"2025090312532307000_7.1.e001512.191","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2010.02.014"},{"key":"2025090312532307000_7.1.e001512.192","doi-asserted-by":"publisher","DOI":"10.3109\/11038128.2011.611820"},{"key":"2025090312532307000_7.1.e001512.193","doi-asserted-by":"publisher","DOI":"10.1002\/art.1790100405"},{"key":"2025090312532307000_7.1.e001512.194","first-page":"292","article-title":"The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study","volume":"11","author":"Roth","year":"2009","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"2025090312532307000_7.1.e001512.195","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2003.08.001"},{"key":"2025090312532307000_7.1.e001512.196","first-page":"261","article-title":"The Cochrane review of assistive technology for rheumatoid arthritis","volume":"46","author":"Tuntland","year":"2010","journal-title":"Eur J Phys Rehabil Med"},{"key":"2025090312532307000_7.1.e001512.197","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/anr.1780320107","article-title":"Development and evaluation of a scale to measure perceived self-efficacy in people with arthritis","volume":"32","author":"Lorig","year":"1989","journal-title":"Arthritis Care Res."},{"key":"2025090312532307000_7.1.e001512.198","doi-asserted-by":"crossref","unstructured":"Kerschbaumer A , Sepriano A , Smolen JS , et al . Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research Informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2020:annrheumdis-2019-216656. doi:10.1136\/annrheumdis-2019-216656","DOI":"10.1136\/annrheumdis-2019-216656"},{"key":"2025090312532307000_7.1.e001512.199","unstructured":"Nagy G , Roodenrijs NMT , Welsing PMJ . EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. Manuscript in preparation."}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2020-001512","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:53:41Z","timestamp":1756929221000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2020-001512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":199,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,8]]},"published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1136\/rmdopen-2020-001512"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2020-001512","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}